Resumo

BANCHERO, Patricia et al. Seguridad de los inhibidores selectivos de la ciclooxigenasa 2. Rev. Méd. Urug. [online]. 2004, vol.20, n.2, pp.136-144. ISSN 1688-0390.

Summary Non steroid antitiflammatory drugs (AINES) are among the most frequently prescribed drugs. Gastrointestinal toxicity is determinant for its long-term use. During last years, selective cyclooxigenase 2 (COX-2) inhibitors have been promoted as safer alternative. Clinical trials that evaluate the gastrointestinal, cardiac and renal toxocoty of these drugs published in the last five years were analyzed in order to evaluate the available evidence about the selective COX-2 inhibitors’ safety. So far, there is no clear evidence that selective COX-2 inhibitors have a better safety profile than classic AINES. The VIGOR trial was the only one to show a reduction of gastroduodenal complications, but arose the problem -still unsolved- of cardiac toxicity. It is likely that selective COX-2 inhibitors have similar adverse events than classic AINES. It is only through critical analysis of medical literature that information from clinical trials can be rationally used for the treatment of patients.

Palavras-chave : INHIBIDORES DE LA CICLOOXIGENASA [toxicidad].

        · resumo em Espanhol | Francês     · texto em Espanhol     · Espanhol ( pdf )